Favorable outcomes of NPM1mut AML patients are due to transcriptional inactivation of FOXM1, presenting a new target to overcome chemoresistance

• I. Khan,
• A. Kaempf,
• S. Raghuwanshi,
• M. Chesnokov,
• X. Zhang,
• Z. Wang,
• A. Domling,
• J. W. Tyner,
• C. Camacho,
• A. L. Gartel

Affiliations

I. Khan

University of Illinois at Chicago, Department of Medicine

A. Kaempf

OHSU Knight Cancer Institute, School of Medicine

S. Raghuwanshi

University of Illinois at Chicago, Department of Medicine

M. Chesnokov

Centro Nacional de Investigaciones Oncológicas (CNIO)

X. Zhang

University of Illinois at Chicago, Department of Medicine

Z. Wang

The Czech Advanced Technology and Research Institute (CATRIN) of Palacký University

A. Domling

The Czech Advanced Technology and Research Institute (CATRIN) of Palacký University

J. W. Tyner

OHSU Knight Cancer Institute, School of Medicine

C. Camacho

Computational and Systems Biology, University of Pittsburgh

A. L. Gartel

University of Illinois at Chicago, Department of Medicine